Ibex Investors LLC purchased a new stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 28,252 shares of the biotechnology company’s stock, valued at approximately $216,000.
Other large investors have also recently modified their holdings of the company. Janus Henderson Group PLC lifted its holdings in BioCryst Pharmaceuticals by 45.0% during the second quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock valued at $63,581,000 after purchasing an additional 3,441,498 shares in the last quarter. Northern Trust Corp lifted its holdings in BioCryst Pharmaceuticals by 2.2% during the second quarter. Northern Trust Corp now owns 1,214,561 shares of the biotechnology company’s stock valued at $6,960,000 after purchasing an additional 25,685 shares in the last quarter. Spark Investment Management LLC purchased a new position in BioCryst Pharmaceuticals during the second quarter valued at approximately $344,000. State of Wisconsin Investment Board lifted its holdings in BioCryst Pharmaceuticals by 79.1% during the second quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock valued at $575,000 after purchasing an additional 44,300 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in BioCryst Pharmaceuticals by 114.2% during the second quarter. Bank of America Corp DE now owns 116,231 shares of the biotechnology company’s stock valued at $666,000 after purchasing an additional 61,960 shares in the last quarter. 91.34% of the stock is currently owned by institutional investors and hedge funds.
Shares of BCRX opened at $8.89 on Thursday. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.25 and a fifty-two week high of $9.70. The firm has a market capitalization of $974.71 million, a P/E ratio of -11.40 and a beta of 1.78. The company has a current ratio of 2.00, a quick ratio of 1.98 and a debt-to-equity ratio of 0.43.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03). BioCryst Pharmaceuticals had a negative return on equity of 141.00% and a negative net margin of 428.00%. The business had revenue of $1.45 million during the quarter, compared to the consensus estimate of $2.53 million. As a group, analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.99 EPS for the current year.
Several research firms have recently commented on BCRX. ValuEngine raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 8th. Royal Bank of Canada boosted their target price on shares of BioCryst Pharmaceuticals to $16.00 and gave the stock a “positive” rating in a report on Tuesday. BidaskClub downgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Zacks Investment Research downgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, November 7th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $8.50 target price on shares of BioCryst Pharmaceuticals in a report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $11.41.
In other news, VP Lynne Powell sold 5,280 shares of the company’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $8.15, for a total value of $43,032.00. Following the transaction, the vice president now directly owns 8,905 shares in the company, valued at $72,575.75. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Alane P. Barnes sold 44,290 shares of the company’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $9.07, for a total transaction of $401,710.30. The disclosure for this sale can be found here. Insiders have sold 131,640 shares of company stock worth $1,127,702 in the last quarter. Company insiders own 4.50% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/12/06/ibex-investors-llc-invests-216000-in-biocryst-pharmaceuticals-inc-bcrx-stock.html.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Featured Article: What are municipal bonds?
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.